Cancer Medicines To Get Cheaper: Govt Caps Trade Margin at 30%, MRP May Drop up to 70%
The government is set to cap trade margins at 30% on expensive cancer drugs, including some patented medicines. MRPs could fall by up to 70%, and the measure is expected to take effect within 10 days.
Cancer patients in India could soon get major relief on treatment costs, as the government is moving to cap trade margins at 30% over the cost to distributors on some of the country's most expensive cancer medicines. According to Department of Pharmaceuticals sources, the move will cover high-priced drugs, including some patented medicines, and could bring down their retail prices (MRPs) by as much as 70%. The decision is aimed at curbing steep mark-ups in the cancer drug market, and the measure is expected to take effect within 10 days.
Who Decides Which Drugs Are Covered?
A committee headed by the Director General of Health Services is now drawing up the list of medicines that will come under the new regime. Drugs being considered must be approved for cancer treatment in India and be in frequent use, apart from meeting the key criterion of being expensive. Health Ministry Bans 16 Fixed Dose Combination Drugs Across Country Over Safety and Efficacy Concerns.
Why Only Costly Drugs?
'An important consideration for selecting a medicine is that it should be expensive,' a Department of Pharmaceuticals official said. The official explained that extending the 30% cap to cheaper drugs could discourage companies from marketing them, as the regulated margin may not adequately cover marketing and distribution costs. The government is therefore targeting medicines where the impact on patients is likely to be greatest, while avoiding a blanket cap that could disrupt the supply and distribution of lower-priced drugs. Union Ministry of Health and Family Welfare Amends Drugs Rules, 1945; Exemption for Sale of Cough Syrups in Small Villages Withdrawn.
Builds On 2019 Pilot
The latest move builds on a 2019 pilot under which trade margins on 42 cancer medicines were capped. In high-priced drugs, even a relatively large margin translates into a substantial increase in the price paid by patients, which is why the focus is now on this segment.
Savings For Patients
For cancer patients and their families, a cut in MRP of up to 70% could mean significant savings, particularly for those requiring prolonged treatment with high-cost drugs. The actual impact, however, will depend on which medicines make the final list and how much of the existing trade margin is passed on to patients.
(The above story first appeared on LatestLY on Oct 08, 2026 06:33 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
